Other lipid-modifying drugs (KTT3) by all CCGs

Why it matters: The latest NICE guidance suggests that, for the vast majority of people who need treatment for high cholesterol, these drugs should not be used. There is no evidence that omega 3 fatty acids reduce the chances of patients getting cardiovascular disease.

Description: Number of prescription items for Bile acid sequestrants, Fibrates, Nicotinic acid, and Omega-3 fatty acid compounds, and 'Other lipid modifying drugs' (BNF 2.12 sub-set) as a percentage of total prescription items for BNF 2.12.

CCGs are ordered by mean percentile over the past six months. Each chart shows the results for the individual CCG, plus deciles across all CCGs in the NHS in England.

Fetching data...

Do you need help with your analysis? We can provide custom extracts from our prescribing data for free. Get in touch to find out more.